Number of patients in million with all types of visual impairmanet
in MENA region (total)
| sex |
age |
Blindness and vision loss |
Presbyopia |
Moderate vision loss |
Severe vision loss |
Blindness |
| Both |
<5 years |
0.6(0.5,0.8) |
0(0,0) |
0.6(0.4,0.7) |
0(0,0.1) |
0(0,0) |
| Both |
15-49 years |
9.6(8.2,11.1) |
2.1(1.3,3.2) |
6.3(5.2,7.3) |
0.6(0.5,0.7) |
0.6(0.5,0.7) |
| Both |
5-14 years |
2.1(1.7,2.6) |
0(0,0) |
1.9(1.5,2.4) |
0.1(0.1,0.1) |
0.1(0.1,0.1) |
| Both |
50-69 years |
14(11.4,17.1) |
6.7(4.3,9.5) |
5.5(4.5,6.6) |
0.9(0.7,1) |
1(0.8,1.2) |
| Both |
70+ years |
10.8(9.1,12.9) |
4.7(3.2,6.9) |
4.1(3.4,4.9) |
0.8(0.6,0.9) |
1.2(0.9,1.4) |
| Both |
All ages |
37.2(32.7,42.1) |
13.5(9.6,18.2) |
18.4(16.5,20.3) |
2.4(2.1,2.7) |
2.9(2.5,3.3) |
| Female |
<5 years |
0.3(0.3,0.4) |
0(0,0) |
0.3(0.2,0.4) |
0(0,0) |
0(0,0) |
| Female |
15-49 years |
4.8(4.1,5.5) |
1(0.6,1.6) |
3.1(2.6,3.6) |
0.3(0.3,0.4) |
0.3(0.2,0.4) |
| Female |
5-14 years |
1.1(0.9,1.3) |
0(0,0) |
0.9(0.7,1.2) |
0.1(0,0.1) |
0(0,0.1) |
| Female |
50-69 years |
7.2(5.9,8.8) |
3.4(2.2,4.8) |
2.8(2.3,3.4) |
0.5(0.4,0.6) |
0.5(0.4,0.6) |
| Female |
70+ years |
5.6(4.8,6.8) |
2.5(1.7,3.6) |
2.1(1.8,2.5) |
0.4(0.3,0.5) |
0.6(0.5,0.8) |
| Female |
All ages |
19(16.7,21.4) |
6.9(4.9,9.3) |
9.3(8.4,10.3) |
1.3(1.1,1.4) |
1.5(1.3,1.7) |
| Male |
<5 years |
0.3(0.3,0.4) |
0(0,0) |
0.3(0.2,0.4) |
0(0,0) |
0(0,0) |
| Male |
15-49 years |
4.8(4.1,5.6) |
1.1(0.7,1.6) |
3.2(2.6,3.7) |
0.3(0.2,0.3) |
0.3(0.3,0.4) |
| Male |
5-14 years |
1.1(0.9,1.3) |
0(0,0) |
1(0.8,1.2) |
0.1(0,0.1) |
0(0,0.1) |
| Male |
50-69 years |
6.8(5.5,8.3) |
3.3(2.1,4.7) |
2.6(2.2,3.2) |
0.4(0.3,0.5) |
0.5(0.4,0.6) |
| Male |
70+ years |
5.1(4.4,6.2) |
2.3(1.5,3.3) |
2(1.7,2.4) |
0.4(0.3,0.4) |
0.6(0.4,0.7) |
| Male |
All ages |
18.2(16,20.6) |
6.6(4.7,9) |
9(8.1,10) |
1.1(1,1.2) |
1.4(1.2,1.6) |
| sex |
age |
Blindness and vision loss |
Presbyopia |
Moderate vision loss |
Severe vision loss |
Blindness |
| Both |
<5 years |
1.29% (1.02,1.62) |
0% (0,0.01) |
1.14% (0.88,1.46) |
0.09% (0.07,0.12) |
0.05% (0.03,0.07) |
| Both |
15-49 years |
2.94% (2.51,3.4) |
0.65% (0.4,0.98) |
1.92% (1.61,2.25) |
0.19% (0.16,0.22) |
0.19% (0.15,0.22) |
| Both |
5-14 years |
2.06% (1.66,2.53) |
0.02% (0.01,0.04) |
1.83% (1.44,2.31) |
0.11% (0.09,0.14) |
0.09% (0.06,0.12) |
| Both |
50-69 years |
17.59% (14.4,21.47) |
8.39% (5.41,11.91) |
6.87% (5.71,8.36) |
1.08% (0.89,1.28) |
1.25% (1,1.53) |
| Both |
70+ years |
55.31% (46.88,66.03) |
24.28% (16.54,35.54) |
21.12% (17.67,24.98) |
3.89% (3.21,4.79) |
6.02% (4.82,7.4) |
| Both |
Age-standardized |
8.6% (7.54,9.81) |
3.36% (2.39,4.56) |
3.95% (3.54,4.38) |
0.56% (0.5,0.63) |
0.73% (0.62,0.84) |
| Both |
All ages |
6.41% (5.64,7.24) |
2.33% (1.66,3.15) |
3.16% (2.84,3.51) |
0.41% (0.37,0.46) |
0.5% (0.43,0.57) |
| Female |
<5 years |
1.27% (1.02,1.6) |
0% (0,0.01) |
1.12% (0.88,1.44) |
0.1% (0.08,0.13) |
0.05% (0.03,0.07) |
| Female |
15-49 years |
3.03% (2.58,3.49) |
0.66% (0.41,1) |
1.97% (1.65,2.31) |
0.2% (0.17,0.24) |
0.19% (0.16,0.23) |
| Female |
5-14 years |
2.03% (1.64,2.5) |
0.02% (0.01,0.03) |
1.8% (1.41,2.28) |
0.12% (0.1,0.15) |
0.09% (0.06,0.12) |
| Female |
50-69 years |
18.67% (15.36,22.69) |
8.8% (5.73,12.44) |
7.34% (6.08,8.92) |
1.22% (1.01,1.44) |
1.31% (1.04,1.6) |
| Female |
70+ years |
57.68% (48.93,69.09) |
25.36% (17.14,36.8) |
21.88% (18.26,25.76) |
4.1% (3.38,5.04) |
6.34% (5.07,7.79) |
| Female |
Age-standardized |
8.86% (7.78,10.07) |
3.45% (2.46,4.66) |
4.05% (3.62,4.48) |
0.6% (0.53,0.68) |
0.75% (0.64,0.87) |
| Female |
All ages |
6.7% (5.91,7.57) |
2.45% (1.74,3.29) |
3.28% (2.94,3.64) |
0.45% (0.4,0.51) |
0.52% (0.45,0.6) |
| Male |
<5 years |
1.3% (1.02,1.63) |
0% (0,0.01) |
1.16% (0.89,1.48) |
0.09% (0.07,0.12) |
0.05% (0.03,0.07) |
| Male |
15-49 years |
2.87% (2.45,3.32) |
0.64% (0.39,0.97) |
1.87% (1.57,2.19) |
0.17% (0.15,0.2) |
0.18% (0.15,0.22) |
| Male |
5-14 years |
2.08% (1.69,2.55) |
0.02% (0.01,0.04) |
1.87% (1.47,2.34) |
0.11% (0.08,0.13) |
0.09% (0.06,0.12) |
| Male |
50-69 years |
16.57% (13.5,20.38) |
8% (5.07,11.47) |
6.43% (5.34,7.9) |
0.95% (0.78,1.12) |
1.2% (0.95,1.46) |
| Male |
70+ years |
52.93% (44.86,63.59) |
23.19% (15.82,33.89) |
20.36% (16.99,24.16) |
3.68% (3.02,4.55) |
5.69% (4.57,7) |
| Male |
Age-standardized |
8.34% (7.29,9.56) |
3.26% (2.31,4.46) |
3.85% (3.45,4.28) |
0.52% (0.46,0.59) |
0.71% (0.6,0.82) |
| Male |
All ages |
6.12% (5.37,6.92) |
2.23% (1.57,3.02) |
3.05% (2.73,3.38) |
0.38% (0.34,0.42) |
0.47% (0.41,0.54) |
Prevalence per 100,000 of vision loss in MENA region in 2019
| sex |
age |
Blindness and vision loss |
Presbyopia |
Moderate vision loss |
Severe vision loss |
Blindness |
| Both |
<5 years |
1086.7(869,1365.7) |
4.1(1.8,7.8) |
962.3(748.5,1229.8) |
80.2(63.2,104.3) |
40.1(26.2,57.3) |
| Both |
15-49 years |
2881.1(2458.4,3331.5) |
634.8(390.7,959.7) |
1880.6(1568.8,2198.2) |
183.6(154.6,215.5) |
182.3(151.4,220.1) |
| Both |
5-14 years |
1847.7(1493.6,2266.3) |
16.7(7.4,31.7) |
1647.7(1292.8,2068.7) |
102.1(81.4,126.5) |
81.2(57.1,109.4) |
| Both |
50-69 years |
17554.1(14363.7,21444.6) |
8370.4(5396.5,11892.4) |
6860.4(5694.4,8342.5) |
1075.1(887.8,1274.5) |
1248.3(997.4,1526.8) |
| Both |
70+ years |
55303.4(46875.5,66021.4) |
24277(16537.1,35538.2) |
21122(17668.4,24981) |
3889.3(3206,4785.2) |
6015.1(4815.5,7398.7) |
| Both |
All ages |
6109.8(5377.1,6908.2) |
2225.8(1578,2997.1) |
3015(2708.2,3338.9) |
393.4(351.2,440.2) |
475.6(407.8,542.3) |
| Female |
<5 years |
1109.3(885.6,1393.9) |
4.2(1.9,7.7) |
977.1(765.3,1248.2) |
87(68.1,113) |
41(26.5,58.6) |
| Female |
15-49 years |
3002.7(2562.7,3462.8) |
655.6(402.9,993.9) |
1957.5(1633.6,2297.6) |
200.7(169.6,235.7) |
189(156.6,228.8) |
| Female |
5-14 years |
1878.1(1511.6,2302.2) |
17(7.6,31.5) |
1665(1304.5,2101.9) |
111(88.3,137.6) |
85.1(60,114.8) |
| Female |
50-69 years |
18655.8(15352.8,22680.4) |
8794.3(5729.4,12431.3) |
7336.2(6074.1,8917.9) |
1216.6(1006.9,1444) |
1308.8(1044.1,1601.1) |
| Female |
70+ years |
57674.3(48924.2,69087.3) |
25360.5(17140.9,36800.8) |
21881.3(18262.8,25760.2) |
4096.8(3381.3,5036.5) |
6335.7(5069.6,7793) |
| Female |
All ages |
6494.1(5719.1,7326.7) |
2369.1(1686.7,3188.5) |
3180.6(2855.3,3518.4) |
436.6(388.9,489.8) |
507.8(435.1,578.6) |
| Male |
<5 years |
1065.3(847.6,1332.4) |
4(1.8,7.9) |
948.3(738,1218) |
73.7(58.4,96.2) |
39.3(25.5,55.8) |
| Male |
15-49 years |
2770.8(2362.6,3209) |
615.9(377.7,942.9) |
1810.7(1510,2118.7) |
168(141,198.1) |
176.1(146.5,212.3) |
| Male |
5-14 years |
1819.1(1466.5,2230.1) |
16.3(7.3,32.2) |
1631.4(1281.7,2046.7) |
93.8(74.9,116.2) |
77.6(54.7,103.7) |
| Male |
50-69 years |
16518.7(13446.8,20319.2) |
7972(5052.4,11432.8) |
6413.1(5321.1,7874.9) |
942.1(778.5,1114) |
1191.5(951.8,1454.4) |
| Male |
70+ years |
52918.3(44856.8,63581.4) |
23186.9(15821,33882.1) |
20358.2(16987.9,24156.1) |
3680.6(3021.1,4552.9) |
5692.6(4572.7,6999.3) |
| Male |
All ages |
5754.3(5051.9,6516) |
2093.2(1473.4,2836.7) |
2861.8(2570.2,3167.2) |
353.5(315.8,394.7) |
445.8(384.9,508.2) |
prevalnce in millions for the causes of vision loss for all ages,
both genders per year (1990-2019)
| rei |
year |
All causes |
Age-related macular degeneration |
Refraction disorders |
Cataract |
Glaucoma |
Diabetes mellitus |
Trachoma |
| Moderate vision loss |
1990 |
9.15(8.22,10.18) |
0.15(0.12,0.19) |
6.25(5.51,7.08) |
1.56(1.28,1.86) |
0.11(0.08,0.14) |
0.16(0.12,0.22) |
0.11(0.08,0.14) |
| Moderate vision loss |
2000 |
11.91(10.65,13.23) |
0.22(0.17,0.28) |
7.94(6.99,8.98) |
2.25(1.86,2.68) |
0.15(0.12,0.2) |
0.21(0.15,0.28) |
0.05(0.03,0.08) |
| Moderate vision loss |
2010 |
15.09(13.51,16.72) |
0.3(0.23,0.38) |
9.79(8.65,11.03) |
3.14(2.59,3.72) |
0.2(0.15,0.26) |
0.27(0.19,0.36) |
0.02(0.01,0.03) |
| Moderate vision loss |
2019 |
18.35(16.48,20.32) |
0.39(0.3,0.5) |
11.46(10.13,12.9) |
4.2(3.45,4.99) |
0.26(0.2,0.33) |
0.34(0.24,0.46) |
0.01(0.01,0.02) |
| Severe vision loss |
1990 |
1.27(1.13,1.41) |
0.03(0.02,0.04) |
0.48(0.42,0.54) |
0.37(0.29,0.45) |
0.02(0.02,0.03) |
0.05(0.04,0.07) |
0.03(0.02,0.03) |
| Severe vision loss |
2000 |
1.59(1.42,1.78) |
0.04(0.03,0.06) |
0.6(0.53,0.68) |
0.49(0.39,0.59) |
0.03(0.02,0.04) |
0.06(0.05,0.09) |
0.01(0.01,0.02) |
| Severe vision loss |
2010 |
1.96(1.75,2.2) |
0.05(0.04,0.07) |
0.72(0.64,0.82) |
0.63(0.51,0.78) |
0.04(0.03,0.05) |
0.08(0.06,0.11) |
0(0,0.01) |
| Severe vision loss |
2019 |
2.39(2.14,2.68) |
0.07(0.05,0.09) |
0.86(0.75,0.98) |
0.82(0.66,1) |
0.05(0.03,0.06) |
0.1(0.07,0.13) |
0(0,0) |
| Blindness |
1990 |
2.02(1.74,2.3) |
0.1(0.07,0.13) |
0.13(0.1,0.15) |
0.66(0.54,0.8) |
0.28(0.22,0.35) |
0.03(0.02,0.04) |
0.06(0.04,0.1) |
| Blindness |
2000 |
2.3(1.99,2.61) |
0.12(0.08,0.16) |
0.14(0.11,0.17) |
0.7(0.57,0.85) |
0.33(0.25,0.41) |
0.04(0.03,0.05) |
0.07(0.04,0.1) |
| Blindness |
2010 |
2.58(2.22,2.93) |
0.15(0.1,0.2) |
0.17(0.14,0.2) |
0.73(0.59,0.89) |
0.38(0.29,0.48) |
0.06(0.04,0.08) |
0.04(0.02,0.06) |
| Blindness |
2019 |
2.9(2.48,3.3) |
0.18(0.13,0.24) |
0.18(0.15,0.22) |
0.78(0.62,0.95) |
0.43(0.33,0.54) |
0.07(0.05,0.1) |
0.02(0.01,0.04) |
Heatmap showing age-standardized prevelance rate per 100,000 in MENA
region countries
| location |
Age-related macular degeneration |
Refraction disorders |
Cataract |
Glaucoma |
Diabetes mellitus |
Trachoma |
| Afghanistan |
210 |
2397 |
2721 |
269 |
92 |
120 |
| Algeria |
161 |
2337 |
1689 |
209 |
123 |
6 |
| Bahrain |
149 |
2301 |
1598 |
182 |
169 |
0 |
| Egypt |
167 |
2606 |
1790 |
212 |
203 |
9 |
| Iran |
277 |
2627 |
1373 |
292 |
103 |
3 |
| Iraq |
161 |
2306 |
1691 |
207 |
163 |
8 |
| Jordan |
120 |
2292 |
762 |
167 |
123 |
0 |
| Kuwait |
145 |
2217 |
1562 |
169 |
104 |
0 |
| Lebanon |
162 |
2584 |
1813 |
168 |
107 |
0 |
| Libya |
115 |
2148 |
1860 |
288 |
213 |
12 |
| Morocco |
109 |
1929 |
1658 |
180 |
92 |
19 |
| Oman |
221 |
3831 |
2654 |
221 |
197 |
256 |
| Palestine |
130 |
2092 |
2040 |
139 |
218 |
0 |
| Qatar |
126 |
2294 |
1547 |
266 |
121 |
0 |
| Saudi Arabia |
232 |
3029 |
2373 |
269 |
116 |
0 |
| Sudan |
140 |
1975 |
1356 |
291 |
99 |
10 |
| Syria |
164 |
2409 |
1710 |
218 |
100 |
0 |
| Tunisia |
138 |
1802 |
1391 |
187 |
89 |
0 |
| Turkey |
107 |
1627 |
1157 |
131 |
66 |
0 |
| UAE |
155 |
2259 |
1559 |
199 |
113 |
0 |
| Yemen |
207 |
2194 |
1421 |
193 |
59 |
35 |
| MENA |
168 |
2277 |
1534 |
208 |
115 |
10 |
| Global |
97 |
1960 |
1208 |
95 |
51 |
23 |
| Low SDI |
139 |
2156 |
1967 |
189 |
50 |
269 |
| Low-middle SDI |
108 |
2771 |
2182 |
122 |
46 |
25 |
| Middle SDI |
111 |
2100 |
1542 |
114 |
69 |
8 |
| High-middle SDI |
106 |
1845 |
894 |
81 |
51 |
1 |
| High SDI |
48 |
1308 |
357 |
50 |
29 |
0 |
Heatmap showing age-standardized prevelance rate per 100,000 in MENA
region countries
| location |
Presbyopia |
Moderate vision loss |
Severe vision loss |
Blindness |
| Afghanistan |
4003 |
4328 |
696 |
1558 |
| Algeria |
3339 |
3900 |
566 |
672 |
| Bahrain |
3152 |
3824 |
535 |
564 |
| Egypt |
3362 |
4372 |
619 |
639 |
| Iran |
2512 |
4090 |
680 |
900 |
| Iraq |
3322 |
3900 |
563 |
705 |
| Jordan |
3190 |
3246 |
476 |
383 |
| Kuwait |
2964 |
3789 |
509 |
466 |
| Lebanon |
3250 |
4288 |
502 |
558 |
| Libya |
3181 |
3770 |
594 |
832 |
| Morocco |
3576 |
3489 |
525 |
479 |
| Oman |
3094 |
6349 |
1051 |
794 |
| Palestine |
3419 |
3933 |
570 |
597 |
| Qatar |
2967 |
3824 |
512 |
564 |
| Saudi Arabia |
3050 |
4904 |
765 |
1232 |
| Sudan |
3636 |
3581 |
559 |
1064 |
| Syria |
3385 |
3918 |
573 |
689 |
| Tunisia |
3297 |
3036 |
446 |
665 |
| Turkey |
3190 |
2776 |
289 |
402 |
| UAE |
2887 |
3732 |
491 |
595 |
| Yemen |
3807 |
3588 |
509 |
885 |
| MENA |
3206 |
3770 |
537 |
699 |
| Global |
5938 |
3153 |
420 |
523 |
| Low SDI |
10200 |
3989 |
693 |
1042 |
| Low-middle SDI |
8940 |
4565 |
702 |
828 |
| Middle SDI |
6699 |
3571 |
477 |
680 |
| High-middle SDI |
5769 |
2874 |
313 |
379 |
| High SDI |
1234 |
1757 |
193 |
146 |
AGe-standarized prevalence rate (per 100,000) for both sexes over
the years 1990,2000,2010,2019
| year |
cause |
Blindness and vision loss |
Moderate vision loss |
Severe vision loss |
Blindness |
| 1990 |
Age-related macular degeneration |
184 |
99 |
21 |
64 |
| 1990 |
Cataract |
1776 |
1074 |
245 |
457 |
| 1990 |
Glaucoma |
302 |
75 |
16 |
211 |
| 1990 |
Diabetes mellitus |
140 |
95 |
29 |
15 |
| 1990 |
Trachoma |
121 |
64 |
15 |
41 |
| 2000 |
Age-related macular degeneration |
183 |
104 |
21 |
58 |
| 2000 |
Cataract |
1704 |
1117 |
235 |
352 |
| 2000 |
Glaucoma |
270 |
76 |
15 |
178 |
| 2000 |
Diabetes mellitus |
133 |
91 |
26 |
16 |
| 2000 |
Trachoma |
61 |
24 |
6 |
31 |
| 2010 |
Age-related macular degeneration |
180 |
106 |
20 |
54 |
| 2010 |
Cataract |
1616 |
1130 |
221 |
265 |
| 2010 |
Glaucoma |
237 |
73 |
14 |
150 |
| 2010 |
Diabetes mellitus |
128 |
86 |
24 |
17 |
| 2010 |
Trachoma |
21 |
6 |
1 |
13 |
| 2019 |
Age-related macular degeneration |
168 |
102 |
18 |
49 |
| 2019 |
Cataract |
1534 |
1115 |
210 |
209 |
| 2019 |
Glaucoma |
208 |
70 |
13 |
126 |
| 2019 |
Diabetes mellitus |
115 |
78 |
21 |
15 |
| 2019 |
Trachoma |
10 |
3 |
1 |
6 |
## # A tibble: 10 × 2
## cause total_val
## <fct> <dbl>
## 1 All causes 37191199.
## 2 Blindness and vision loss 35586460.
## 3 Near vision loss 13548646.
## 4 Refraction disorders 12503611.
## 5 Cataract 5795855.
## 6 Other vision loss 2363506.
## 7 Glaucoma 733620.
## 8 Age-related macular degeneration 641221.
## 9 Diabetes mellitus 503834.
## 10 Trachoma 39390.
## [1] 0 500 1000 1500 2000
## [1] 0 500 1000 1500 2000
## [1] 0 500 1000 1500 2000
## [1] 0 500 1000 1500 2000
## [1] 0 1000 2000 3000 4000 5000 6000 7000
## [1] 0 1000 2000 3000 4000 5000 6000 7000
## [1] 0 1000 2000 3000 4000 5000 6000 7000
## [1] 0 1000 2000 3000 4000 5000 6000 7000
## [1] 0 500 1000 1500 2000
## [1] 0 500 1000 1500 2000
## [1] 0 500 1000 1500 2000
## [1] 0 500 1000 1500 2000
